Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

251 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Monitoring antigen-specific biologics: current knowledge and future prospects.
Zandvliet ML, van Bezooijen JS, Bos MA, Prens EP, van Doorn M, Bijen I, Schreurs MW, van der Velden VH, Koch BC, van Gelder T. Zandvliet ML, et al. Among authors: van der velden vh, van gelder t, van doorn m, van bezooijen js. Ther Drug Monit. 2013 Oct;35(5):588-94. doi: 10.1097/FTD.0b013e318295f6b2. Ther Drug Monit. 2013. PMID: 23942545 Review.
Antibodies Against Angiotensin II Receptor Type 1 and Endothelin A Receptor Are Associated With an Unfavorable COVID19 Disease Course.
Miedema J, Schreurs M, van der Sar-van der Brugge S, Paats M, Baart S, Bakker M, Hoek R, Dik WA, Endeman H, Van Der Velden V, van Gammeren A, Ermens A, Aerts JG, Thüsen JV. Miedema J, et al. Front Immunol. 2021 May 13;12:684142. doi: 10.3389/fimmu.2021.684142. eCollection 2021. Front Immunol. 2021. PMID: 34054876 Free PMC article.
Dasatinib in children and adolescents with relapsed or refractory leukemia: results of the CA180-018 phase I dose-escalation study of the Innovative Therapies for Children with Cancer Consortium.
Zwaan CM, Rizzari C, Mechinaud F, Lancaster DL, Lehrnbecher T, van der Velden VH, Beverloo BB, den Boer ML, Pieters R, Reinhardt D, Dworzak M, Rosenberg J, Manos G, Agrawal S, Strauss L, Baruchel A, Kearns PR. Zwaan CM, et al. Among authors: van der velden vh. J Clin Oncol. 2013 Jul 1;31(19):2460-8. doi: 10.1200/JCO.2012.46.8280. Epub 2013 May 28. J Clin Oncol. 2013. PMID: 23715577 Clinical Trial.
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Cavo M, Gay F, Beksac M, Pantani L, Petrucci MT, Dimopoulos MA, Dozza L, van der Holt B, Zweegman S, Oliva S, van der Velden VHJ, Zamagni E, Palumbo GA, Patriarca F, Montefusco V, Galli M, Maisnar V, Gamberi B, Hansson M, Belotti A, Pour L, Ypma P, Grasso M, Croockewit A, Ballanti S, Offidani M, Vincelli ID, Zambello R, Liberati AM, Andersen NF, Broijl A, Troia R, Pascarella A, Benevolo G, Levin MD, Bos G, Ludwig H, Aquino S, Morelli AM, Wu KL, Boersma R, Hajek R, Durian M, von dem Borne PA, Caravita di Toritto T, Zander T, Driessen C, Specchia G, Waage A, Gimsing P, Mellqvist UH, van Marwijk Kooy M, Minnema M, Mandigers C, Cafro AM, Palmas A, Carvalho S, Spencer A, Boccadoro M, Sonneveld P. Cavo M, et al. Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30. Lancet Haematol. 2020. PMID: 32359506 Clinical Trial.
Effect of a stable Angiotensin-(1-7) analogue on progenitor cell recruitment and cardiovascular function post myocardial infarction.
Sevá Pessôa B, Becher PM, Van Veghel R, De Vries R, Tempel D, Sneep S, Van Beusekom H, Van Der Velden VH, Westermann D, Danser AH, Roks AJ. Sevá Pessôa B, et al. Among authors: van der velden vh, van veghel r, van beusekom h. J Am Heart Assoc. 2015 Feb 5;4(2):e001510. doi: 10.1161/JAHA.114.001510. J Am Heart Assoc. 2015. PMID: 25655571 Free PMC article.
251 results